Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt ...

Fintel reports that on May 28, 2025, Leerink Partners downgraded their outlook for Boundless Bio (NasdaqGS:BOLD) from ...

Fintel reports that on May 28, 2025, Leerink Partners downgraded their outlook for Rocket Pharmaceuticals (NasdaqGM:RCKT) ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

On Tuesday, Leerink Partners made a significant adjustment to the price target of Lexeo Therapeutics (NASDAQ: LXEO) shares, reducing it to $10.00 from the previous $16.00, while still maintaining ...

Four years after selling his namesake bank — a major player in Boston’s biotech scene — to SVB, Jeff Leerink has pulled it out of the rubble of the formerly high-flying tech lender’s crash ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to an acquisition by Transcarent. The firm views the ...

Leerink Partners hired Rothschild & Co. managing director Timothy Hotchandani to focus on health-care dealmaking involving life-science tools and diagnostics companies, according to people with ...

Leerink notes that shares of Outperform-rated Sarepta (SRPT) are under pressure on the heels of the disclosure of a patient death following Elevidys treatment. While an “incredibly sad ...

Likewise, Leerink Partners downgraded the stock to ‘Market Perform’ from an ‘Outperform’ and cut the price target to $8 from $37 on May 28. The downgrade comes on Rocket Pharmaceutical ...